Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Anil TombakFunda Pepedil TanrıkuluSalih Sertaç DurusoyHüseyin Derya DinçyürekEmin KayaElif Gülsüm ÜmitIrfan YavasogluÖzgür MehtapBurak DeveciMehmet Ali ÖzcanHatice TerziMüfide Okay ÖzgeyikNilgün SayınalpMehmet YılmazVahap OkanAlperen KizikliÖmer ÖzcanGüven ÇetinSinan Demirciogluİsmet AydoğduGüray SaydamEren Arslan DavulcuGül İlhanMehmet Ali UçarGülsüm ÖzetSeval AkpınarBurhan Turgutİlhami BerberErdal KurtoğluMehmet SönmezDerya Selim BaturRahşan YıldırımVildan ÖzkocamazAhmet Kürşad GüneşŞehmus ErtopOlga Meltem Akay YanarAbdülkadir BaştürkMehmet Hilmi DoguAydan AkdenizAli ÜnalAhmet SeyhanliEmel GürkanDemet ÇekdemirBurhan FerhanoğluPublished in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2021)
This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.